Federal Initiative to Guarantee Health by Targeting Fentanyl Act
- Bill Number
- H.R. 920
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2025-02-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-04-01T19:41:11Z
AI-Generated Summary
Purpose
The Federal Initiative to Guarantee Health by Targeting Fentanyl Act (H.R. 920) aims to combat the fentanyl crisis by classifying a wide range of fentanyl-related substances as Schedule I controlled substances under the Controlled Substances Act (CSA). Schedule I drugs are those with a high potential for abuse, no currently accepted medical use in the U.S., and a lack of accepted safety for use under medical supervision. This legislation seeks to close loopholes that allow new synthetic variants of fentanyl to evade existing drug controls.
Key Provisions
- Addition to Schedule I: Amends Section 202(c) of the CSA to include in Schedule I any material, compound, mixture, or preparation containing fentanyl-related substances, including their salts, isomers (chemically similar variants), and salts of isomers.
- Definition of Fentanyl-Related Substances: Defines these as substances structurally related to fentanyl through specific chemical modifications, such as:
- Replacing the phenyl portion of the phenethyl group with any monocycle (a single-ring chemical structure), whether substituted or not.
- Substituting the phenethyl group with groups like alkyl (carbon chains), alkenyl (unsaturated carbon chains), alkoxyl, hydroxyl, halo (halogen atoms like chlorine), haloalkyl, amino, or nitro.
- Substituting the piperidine ring (a key part of fentanyl's structure) with similar groups, including esters and ethers.
- Replacing the aniline ring with any aromatic monocycle, whether substituted.
- Replacing the N-propionyl group with another acyl group (a type of organic acid derivative).
- Sentencing Adjustment: Amends Section 401(b)(1)(C) of the CSA to exempt offenses involving these new Schedule I substances from mandatory minimum prison terms. (This applies to certain trafficking or distribution offenses that previously required a minimum sentence.)
Significant Changes to Existing Law
- Broadens Drug Scheduling: Previously, the CSA scheduled specific fentanyl analogs individually, which allowed chemists to create slight variations to avoid classification. This bill introduces a catch-all category based on structural similarities, automatically scheduling new variants without needing separate congressional or administrative action.
- Eliminates Mandatory Minimums: Removes required minimum sentences (e.g., 5 years for certain offenses) for violations involving these substances, giving judges more discretion in sentencing. This contrasts with stricter penalties for other Schedule I drugs like heroin or classic fentanyl.
Potential Impacts
- On Government Agencies: The Drug Enforcement Administration (DEA) will gain authority to enforce controls on a wider array of substances without frequent rescheduling, potentially streamlining enforcement but increasing workload for testing and prosecution. It may also reduce federal prison populations by avoiding mandatory minimums.
- On Citizens: Individuals involved in possession, distribution, or manufacturing of these substances face federal criminal penalties (up to life imprisonment for severe cases), but without mandatory minimums, sentences could be lighter, affecting sentencing equity. It targets illicit drug markets, potentially reducing overdose deaths from fentanyl variants, but could impact those in legitimate research or medical fields if exemptions are not clearly applied.
- On International Relations: By targeting synthetic opioids often produced abroad (e.g., in China or Mexico), it could pressure international partners for better precursor chemical controls and cooperation in interdiction efforts, aligning with U.S. anti-drug diplomacy.
Main Stakeholders Affected
- Law Enforcement and Prosecutors: Benefit from easier classification and prosecution of emerging fentanyl variants.
- Drug Traffickers and Users: Face heightened risks of federal charges, though flexible sentencing may allow for alternatives like diversion programs.
- Medical and Research Communities: Could face restrictions on handling these substances for legitimate purposes, requiring DEA exemptions or approvals.
- Federal Judiciary: Gains discretion in sentencing, potentially leading to more individualized justice.
- Public Health Advocates and Overdose Victims' Families: Likely supported, as it addresses the fentanyl epidemic responsible for tens of thousands of U.S. deaths annually.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The broad structural definition may raise challenges under the void-for-vagueness doctrine (a legal principle requiring laws to be clear enough to provide fair notice), as it could inadvertently capture unintended chemicals. However, it builds on existing analog provisions in the CSA, which courts have upheld.
- Constitutional Implications: Aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause, but the removal of mandatory minimums could be seen as a step toward reducing disproportionate punishments, echoing Eighth Amendment concerns about cruel and unusual sentences.
- Political Implications: Reflects bipartisan concern over the opioid crisis, with introduction by Representatives Buchanan (R) and Pappas (D). It balances aggressive drug control with sentencing reform, potentially appealing to both tough-on-crime and criminal justice reform advocates, but may spark debate over federal overreach into state drug policies.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-02-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-04: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-04: Introduced in House
- 2025-02-04: Introduced in House
Bill Versions
- Federal Initiative to Guarantee Health by Targeting Fentanyl Act — issued 2025-02-04 — PDF (3 pages)